J&J(US:JNJ) ZACKSยท2025-09-11 22:45Core Viewpoint - Johnson & Johnson is set to release its earnings report on October 14, 2025, with expectations of significant growth in both EPS and revenue compared to the previous year [2][3]. Company Performance - Johnson & Johnson's stock closed at $178.41, reflecting a daily increase of 1.49%, outperforming the S&P 500's gain of 0.85% [1]. - Over the past month, the stock has appreciated by 0.79%, underperforming the Medical sector's gain of 6.01% and the S&P 500's gain of 2.38% [1]. Earnings Estimates - The upcoming earnings report is anticipated to show an EPS of $2.78, indicating a growth of 14.88% year-over-year, with projected revenue of $23.74 billion, reflecting a 5.63% increase [2]. - Full-year estimates predict earnings of $10.86 per share and revenue of $93.41 billion, representing year-over-year changes of +8.82% and +5.17%, respectively [3]. Analyst Sentiment - Recent adjustments to analyst estimates for Johnson & Johnson are being closely monitored, as upward revisions indicate positive sentiment regarding the company's business operations [4]. - The Zacks Rank system, which reflects these estimate changes, currently rates Johnson & Johnson as 2 (Buy) [6]. Valuation Metrics - Johnson & Johnson is trading at a Forward P/E ratio of 16.19, which is higher than the industry's Forward P/E of 14.14 [7]. - The company has a PEG ratio of 2.24, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.57 [7]. Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 159, placing it in the bottom 36% of over 250 industries [8].